Colfosceril Polmitate
Colfosceril palmitate is a phospholipid. It forms an important constituent of natural and many synthetic pulmonary surfactant compounds. Endogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting pressures. Deficiency of surfactant causes respiratory distress syndrome (RDS) in premature infants. Colfosceril lowers minimum surface tension on alveolar surfaces and restores pulmonary compliance and oxygenation in premature infants.Endotracheal Prophylaxis Infant: Intratracheal 3 doses of 5 mL/kg are recommended, with the first dose being given as soon as possible after birth and repeat doses 12 and 24 h later to infants who remain on mechanical ventilation Rescue Therapy Infant: Intratracheal 2 doses of 5 mL/kg are recommended, the first dose being initiated as soon as the diagnosis of RDS is confirmed and the second 12 h later in infants remaining on mechanical ventilation
Infants who have major congenital abnormalities or who are suspected of having congenital infections.
Monitor continuously for 30 min following administration. ECG and transcutaneous monitoring are required, frequent arterial blood gas sampling is required
Bradycardia, tachycardia, Decreased oxygen saturation, mucous plugging, apnea, pulmonary hemorrhage.
No clinically significant interactions established.
Brand Name | Manufactured by |
---|---|
SURFACT | Sun Pharmaceutical Industries Ltd. |